Glucokinase (GCK) and other susceptibility genes for beta-cell dysfunction: the candidate approach.
There are well-documented examples in the literature of where determining the genetic aetiology of a disorder has provided insights into important regulatory pathways and protein interactions, and, more recently, has led to improved treatment options for patients. The studies of monogenic forms of b...
Principais autores: | Gloyn, A, Tribble, N, van de Bunt, M, Barrett, A, Johnson, P |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2008
|
Registros relacionados
-
Prevalence of glucokinase (GCK) mutations in people with elevated fasting glucose levels: implications for clinical trials
por: Gloyn, A, et al.
Publicado em: (2007) -
Identification and functional characterisation of novel inactivating glucokinase mutations causing GCK-MODY in Slovakia
por: Valentinova, L, et al.
Publicado em: (2011) -
Identification of a novel beta cell glucokinase (GCK) promoter mutation (-71 G > C) which reduces promoter activity
por: Gasperikova, D, et al.
Publicado em: (2008) -
Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation.
por: Christesen, H, et al.
Publicado em: (2008) -
Identification of a Novel beta-Cell Glucokinase (GCK) Promoter Mutation (-71G > C) That Modulates GCK Gene Expression Through Loss of Allele-Specific Sp1 Binding Causing Mild Fasting Hyperglycemia in Humans
por: Gasperikova, D, et al.
Publicado em: (2009)